Billionaire investor Phillip Frost filed an amended 13D regarding New York based Castle Brands Inc. (NYSE:ROX) disclosing an increase of 40 thousand shares in his holdings. Frost didn’t buy or sell any shares since 2014, the last time he filed a 13D. This time Frost has option vested that gives him the right to purchase 40K shares.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Phillip Frost, M.D | 819,776 | 53,093,886 | 819,776 | 53,093,886 | 53,913,662 | 33.6% |
Frost Gamma Investments Trust | 0 | 43,723,096 | 0 | 43,723,096 | 43,723,096 | 27.2% |
Frost Nevada Investments Trust | 0 | 9,370,790 | 0 | 9,370,790 | 9,370,790 | 5.9% |
Page 1 of 6 SEC Filing
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13D/A
INFORMATION TO BE INCLUDED IN STATEMENT
FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS
THERETO FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment No. 9)*
Castle
Brands Inc.
(Name of Issuer)
Common
Stock, par value $0.01 per share
(Title of Class of Securities)
148435100
(CUSIP Number)
Steven
D. Rubin
4400 Biscayne Boulevard, Suite 1500
Miami, Florida 33137
Telephone: (305) 575-6015
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February
9, 2016
(Date of Event Which Requires Filing of
this Statement)
If the filing person
has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.
Note. Schedules
filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See §
240.13d-7 for other parties to whom copies are to be sent.
————————————————
*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
Follow Castle Brands Inc (NYSEMKT:ROX)
Follow Castle Brands Inc (NYSEMKT:ROX)
Page 2 of 6 SEC Filing
CUSIP No. 148435100 | 13D/A | Page 2 of 6 Pages |
1 | Names of Reporting Persons Phillip Frost, M.D. | |||
2 | Check The Appropriate Box if a Member of a Group | |||
(see instructions) | (a) ¨ | |||
(b) ¨ | ||||
3 | SEC Use Only | |||
4 | Source of Funds OO | |||
5 | Check ¨ | |||
6 | Citizenship or Place United States of America | |||
Number Shares Beneficially Owned Each Reporting Person With | 7 | Sole Voting Power 819,776 (1) | ||
8 | Shared Voting Power 53,093,886 (2)(3) | |||
9 | Sole Dispositive Power 819,776 (1) | |||
10 | Shared Dispositive Power 53,093,886 (2)(3) | |||
11 | Aggregate Amount Beneficially 53,913,662 (1)(2)(3) | |||
12 | Check ¨ | |||
13 | Percent of Class Represented 33.6% (4) | |||
14 | Type of Reporting Person IN | |||
(1) Includes vested options (including options that will be exercisable within 60 days of the date hereof) to purchase 40,000 Common
Shares (as defined herein).
(2) Includes (i) 43,167,540 Common Shares held by the Gamma
Trust (as defined herein) and (ii) 555,556 Common Shares issuable upon conversion of $500,000 aggregate principal amount of the
Convertible Note (as defined herein) held by the Gamma Trust. Does not include Common Shares issuable upon the conversion of accrued
but unpaid interest on the Convertible Note, which is payable in cash on a quarterly basis; the Convertible Note and accrued but
unpaid interest thereon is convertible into Common Shares in whole or in part from time to time at the option of the holder.
(3) Includes 9,370,790 Common Shares held by the Nevada Trust
(as defined herein).
(4) The calculation of the percentage is based on (i) 160,034,464Common
Shares outstanding as of February 8, 2016, as reported on the 10-Q filed on February 9, 2016, (ii) 40,000 Common Shares to be issued
upon the exercise of vested options (including options that will be exercisable within 60 days of the date hereof) held by the
Reporting Person and (iii) 555,556 Common Shares issuable upon conversion of $500,000 aggregate principal amount of the Convertible
Note held by the Gamma Trust.
Follow Castle Brands Inc (NYSEMKT:ROX)
Follow Castle Brands Inc (NYSEMKT:ROX)
Page 3 of 6 SEC Filing
CUSIP No. 148435100 | 13D/A | Page 3 of 6 Pages |
1 | Names of Reporting Persons Frost Gamma Investments Trust
| |||
2 | Check The Appropriate Box if a Member of a Group | |||
(see instructions) | (a) ¨ | |||
(b) ¨ | ||||
3 | SEC Use Only | |||
4 | Source of Funds WC | |||
5 | Check ¨ | |||
6 | Citizenship or Place Florida | |||
Number Shares Beneficially Owned Each Reporting Person | 7 | Sole Voting Power 0 | ||
8 | Shared Voting Power 43,723,096 (1) | |||
9 | Sole Dispositive Power 0 | |||
10 | Shared Dispositive Power 43,723,096 (1) | |||
11 | Aggregate Amount Beneficially 43,723,096 (1) | |||
12 | Check ¨ | |||
13 | Percent of Class Represented 27.2% (2) | |||
14 | Type of Reporting Person OO | |||
(1) Includes (i) 43,167,540 Common Shares held by the Gamma Trust and (ii) 555,556 Common Shares issuable upon conversion of $500,000
aggregate principal amount of the Convertible Note held by the Gamma Trust. Does not include Common Shares issuable upon the conversion
of accrued but unpaid interest on the Convertible Note, which is payable in cash on a quarterly basis; the Convertible Note and
accrued but unpaid interest thereon is convertible into Common Shares in whole or in part from time to time at the option of the
holder.
(2) The calculation of the percentage is based on (i) 160,034,464
Common Shares outstanding as of February 8, 2016, as reported on the 10-Q filed on February 9, 2016, and (ii) 555,556 Common Shares
issuable upon conversion of $500,000 aggregate principal amount of the Convertible Note held by the Gamma Trust.
Follow Castle Brands Inc (NYSEMKT:ROX)
Follow Castle Brands Inc (NYSEMKT:ROX)
Page 4 of 6 SEC Filing
CUSIP No. 148435100 | 13D/A | Page 4 of 6 Pages |
1 | Names of Reporting Persons Frost Nevada Investments Trust
| |||
2 | Check The Appropriate Box if a Member of a Group | |||
(see instructions) | (a) ¨ | |||
(b) ¨ | ||||
3 | SEC Use Only | |||
4 | Source of Funds WC | |||
5 | Check ¨ | |||
6 | Citizenship or Place Florida | |||
Number Shares Beneficially Owned Each Reporting Person With | 7 | Sole Voting Power 0 | ||
8 | Shared Voting Power 9,370,790 | |||
9 | Sole Dispositive Power 0 | |||
10 | Shared Dispositive Power 9,370,790 | |||
11 | Aggregate Amount Beneficially 9,370,790 | |||
12 | Check ¨ | |||
13 | Percent of Class Represented 5.9% (1) | |||
14 | Type of Reporting Person OO | |||
(1) The calculation of the percentage is based on 160,034,464 Common Shares outstanding as of February 8, 2016, as reported on
the 10-Q filed on February 9, 2016.
Follow Castle Brands Inc (NYSEMKT:ROX)
Follow Castle Brands Inc (NYSEMKT:ROX)
Page 5 of 6 SEC Filing
CUSIP No. 148435100 | 13D/A | Page 5 of 6 Pages |
SCHEDULE 13D/A
AMENDMENT NO. 9 TO SCHEDULE 13D
This Amendment No. 9 to Schedule 13D (this
“Amendment”) amends certain Items of the Schedule 13D (the “Original 13D”) filed by Phillip Frost, M.D.,
an individual (“Frost”), Frost Gamma Investments Trust, a trust organized under the laws of Florida (the “Gamma
Trust”), and Frost Nevada Investments Trust, a trust organized under the laws of Florida (the “Nevada Trust”,
and together with the Gamma Trust, the “Trusts”; and the Trusts, together with Frost, each a “Reporting Person”
and together the “Reporting Persons”) with the Securities and Exchange Commission (the “SEC”) on September
15, 2008, as amended by Amendment No. 1 to Schedule 13D filed on October 22, 2008 with the SEC, Amendment No. 2 to Schedule 13D
filed on February 20, 2009 with the SEC, Amendment No. 3 to Schedule 13D filed on May 27, 2009, Amendment No. 4 to Schedule 13D
filed on July 6, 2010, Amendment No. 5 to Schedule 13D filed on June 20, 2011, Amendment No. 6 to Schedule 13D filed on October
26, 2011, Amendment No. 7 to Schedule 13D filed on March 14, 2014, and Amendment No. 8 to Schedule 13D filed on August 15, 2014,
with respect to the common stock, par value $0.01 per share (the “Common Shares”), of Castle Brands Inc., a Florida
corporation and successor by merger to Castle Brands Inc., a Delaware corporation (the “Issuer”), by furnishing the
information set forth below. Except as set forth below, all previous Items are unchanged. Capitalized terms used but not defined
herein shall have the meanings ascribed thereto in the Original 13D, as amended.
Based on the most recently disclosed number
of outstanding Common Shares, the Reporting Persons are filing this Amendment to report a decrease in their respective current
beneficial ownership percentages of the Issuer’s Common Shares, resulting solely from an increase in the number of outstanding
Common Shares.
Item 5. Interest in Securities of the Issuer
(a) and (b) Items 5(a) and 5(b) are hereby deleted
in their entirety and replaced with the following:
The Reporting Persons beneficially own
Common Shares as follows:
Name | Number of Common Shares | Sole or Shared Voting | Sole or Shared Dispositive | % of Total Outstanding | ||||
Phillip Frost, M.D. | 819,776(1) | Sole | Sole | 0.5%(2) | ||||
53,093,886(3)(4) | Shared(5)(6) | Shared(5)(6) | 33.1%(7) | |||||
Total: | 53,913,662 (1)(3)(4) | 33.6%(8) | ||||||
Frost Gamma Investments Trust | 43,723,096(3) | Shared(5) | Shared(5) | 27.2%(7) | ||||
Frost Nevada Investments Trust | 9,370,790 | Shared(6) | Shared(6) | 5.9%(9) |
(1) Includes vested options (including options that will be
exercisable within 60 days of the date hereof) to purchase 40,000 Common Shares.
(2) The calculation of the percentage is
based on (i) 160,034,464 Common Shares outstanding as of February 8, 2016, as reported on the 10-Q filed on February 9, 2016, and
(ii) 40,000 Common Shares to be issued upon the exercise of vested options (including options that will be exercisable within 60
days of the date hereof) held by the Reporting Person.
(3) Includes (i) 43,167,540 Common Shares held by the Gamma
Trust and (ii) 555,556 Common Shares issuable upon conversion of $500,000 aggregate principal amount of the Convertible Note held
by the Gamma Trust. Does not include Common Shares issuable upon the conversion of accrued but unpaid interest on the Convertible
Note, which is payable in cash on a quarterly basis; the Convertible Note and accrued but unpaid interest thereon is convertible
into Common Shares in whole or in part from time to time at the option of the holder.
Follow Castle Brands Inc (NYSEMKT:ROX)
Follow Castle Brands Inc (NYSEMKT:ROX)
Page 6 of 6 SEC Filing
CUSIP No. 148435100 | 13D/A | Page 6 of 6 Pages |
(4) Includes 9,370,790 Common Shares held by the Nevada Trust.
(5) Frost is the sole trustee of the Gamma
Trust and may be deemed to share beneficial ownership of the securities held by the Gamma Trust with the Gamma Trust. Frost Gamma
Limited Partnership is the sole and exclusive beneficiary of the Gamma Trust. Frost is one of two limited partners of Frost Gamma
Limited Partnership. The general partner of Frost Gamma Limited Partnership is Frost Gamma, Inc. and the sole shareholder of Frost
Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation.
(6) Frost is the sole trustee of the Nevada
Trust and may be deemed to share beneficial ownership of the securities held by the Nevada Trust with the Nevada Trust. Frost-Nevada
Limited Partnership is the sole and exclusive beneficiary of the Nevada Trust. Frost is one of five limited partners of Frost-Nevada
Limited Partnership and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada Limited Partnership.
(7) The calculation of the percentage is
based on (i) 160,034,464 Common Shares outstanding as of February 8, 2016, as reported on the 10-Q filed on February 9, 2016, and
(ii) 555,556 Common Shares issuable upon conversion of $500,000 aggregate principal amount of the Convertible Note held by the
Gamma Trust.
(8) The calculation of the percentage is
based on (i) 160,034,464 Common Shares outstanding as of February 8, 2016, as reported on the 10-Q filed on February 9, 2016, (ii)
40,000 Common Shares to be issued upon the exercise of vested options (including options that will be exercisable within 60 days
of the date hereof) held by the Reporting Person and (iii) 555,556 Common Shares issuable upon conversion of $500,000 aggregate
principal amount of the Convertible Note held by the Gamma Trust.
(9) The calculation of the percentage is
based on 160,034,464 Common Shares outstanding as of February 8, 2016, as reported on the 10-Q filed on February 9, 2016.
(c) Item
5(c) is hereby deleted in its entirety and replaced with the following:
During the past 60
days prior to the date hereof, the following transactions occurred:
On February 19, 2016,
Frost exercised (i) an option to purchase 100,000 Common Shares at an exercise price of $0.35 per Common Share, (ii) an option
to purchase 20,000 Common Shares at an exercise price of $0.23 per Common Share, (iii) an option to purchase 20,000 Common Shares
at an exercise price of $0.29 per Common Share, (iv) an option to purchase 20,000 Common Shares at an exercise price of $0.27 per
Common Share and (v) an option to purchase 20,000 Common Shares at an exercise price of $0.29 per Common Share.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated as of March 2, 2016
/s/ Phillip Frost, M.D. | |
Phillip Frost, M.D. | |
FROST GAMMA INVESTMENTS TRUST | |
By: /s/ Phillip Frost, M.D. | |
Name: Phillip Frost, M.D. | |
Title: Trustee | |
FROST NEVADA INVESTMENTS TRUST | |
By: /s/ Phillip Frost, M.D. | |
Name: Phillip Frost, M.D. | |
Title: Trustee |